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Deficient feedback regulation of erythropoiesis in kidney transplant
patients with polycythemia. Anemia of endstage renal failure improves
shortly after kidney transplantation. However, in about 10% of trans-
planted patients polycythemia occurs. By use of a sensitive in vitro
bioassay the pathogenetic role of erythropoietin (Ep) was investigated
in 12 patients with post-transplant erythrocytosis (PTE), and compared
to 12 non-PTE patients. The mean Ep of 160 mU/mi was significantly
elevated in patients with PTE as compared to 25 mU/mi of 36 healthy
controls, whereas, the mean Ep of 24 mU/mI in non-PTE patients did
not differ significantly from healthy controls. To further elucidate the
mechanism of inappropriate Ep production, selective venous catheter-
ization of native and transplanted kidneys was performed in six
patients. In four PTE patients the mean Ep in native kidney veins of 110
mU/mi was significantly higher than the peripheral Ep of 66 mU/mi,
whereas, mean Ep in kidney graft veins was 51 mU/mi. In contrast, in
two non-PTE patients no significant difference between mean Ep from
native and transplanted kidney veins was observed. We conclude that
some patients escape from normal feedback regulation either due to
autonomous Ep production or due to feedback regulation at an elevated
level of hematocrit and that inappropriate Ep production originates
from the diseased native kidneys.
Trouble du rétro-contrôie de l'érythropoiese chez des transplantés
rénaux avec une polycythémie. L'anémie de l'insuffisance rénale termin-
ale s'améliore rapidement apres transplantation rénale. Cependant,
chez environ 10% des transplantés, une polycythémie survient. En
utilisant un bioassay sensible in vitro, le role pathogenique de l'erythro-
poIétine (Ep) a été étudié chez 12 malades atteints d'une erythrocytose
post-transplantation (PTE) et compare a 12 malades non-PTE. L'Ep
moyenne de 160 mU/mi était significativement élevée chez les malades
avec PTE par rapport aux 25 mU/mI de 36 sujets sains, tandis que Ep
moyenne de 24 mU/mI chez les malades non-PTE ne différait significa-
tivement des contrOles sains. Afin de préciser mieux le mécanisme de Ia
production inappropriée d'Ep, une cathétérisation veineuse selective
des reins propre et transplante a éte faite chez 6 malades. Chez quatre
malades PTE, l'Ep moyenne dans les veines du rein propre était de 110
mU/mI, significativement plus élevée que I'Ep périphérique de 66 mU/
ml, tandis que l'Ep moyenne des veines du greffon renal était de 51 mU/
ml. Au contraire, chez deux malades non-PTE, aucune difference
significative entre l'Ep moyenne dans les veines du rein propre ou
transplante n'a été observée. Nous concluons que certains malades
echappent au rétro-contrOle normal soit par une production autonome
d'Ep, soit par un rdtro-contrOle a un niveau élevé d'hématocrite et que
Ia production inappropriée d'Ep prend son origine a partir des reins
propres malades.
Anemia progresses during the course of chronic renal failure
with deterioration of excretory kidney function [1—3]. Erythro-
poietin (Ep) deficiency [1, 2] and uremic bone marrow intoxica-
tion [4, 5] have been implicated as major causative factors for
the development of renal anemia. This concept is supported by
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the observation that 3 to 5 months following successful kidney
transplantation hemoglobin concentration returns to normal in
the majority of patients [6, 7]. However, in some patients the
hematocrit continues to rise even after complete correction of
anemia resulting in post-transplant erythrocytosis (PTE) [6—9].
Since differentiation and maturation of red cells is under the
control of Ep, elevated Ep concentrations have been suspected
as being responsible for the increased erythropoiesis in PTE
patients [6—10]. Several pathogenetic factors have been impli-
cated in the development of renal hypoxia resulting in elevated
Ep levels and include cardiac insufficiency, pulmonary dis-
eases, renal artery stenosis, and rejection episodes [6, 9, 11,
12]. However, none of these conditions occurs more frequently
in patients with PTE than in transplant patients with normal
hematocrits [6, 8, 9, 12], thus excluding hypoxia as the cause of
erythrocytosis.
Recently, Dagher et al [7] reported elevated peripheral Ep
concentrations in patients with PTE. These authors claim that
the native kidneys are the source of increased Ep production,
which contrasts the generally accepted concept that the dam-
aged kidneys are unable to produce sufficient Ep in endstage
renal failure [1, 2, 12, 13].
To elucidate further the regulation of erythropoiesis and the
role of Ep in kidney transplant patients, we determined periph-
eral Ep concentrations in a group of patients with PTE and
compared them to a similar group of patients with almost
normal hematocrit. In addition, the contribution of native and
transplant kidneys to Ep production was investigated in some of
these patients with and without PTE by use of selective venous
catheterization.
Methods
Patients. Among 82 patients with well functioning kidney
grafts, 12 patients exhibited a rapid increase in hematocrit from
a mean of 25 to 50% within 4 months after transplantation.
These patients represented one of the two groups studied. To
prevent thromboembolic events in these patients the hematocrit
was kept at around 50% by intermittent phlebotomy. With the
removal of an average amount of 2500 ml blood (5 x 500 ml),
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Table 1. Clinical and laboratory data of patients with (PTE) and without (non-PTE) post-transplant erythrocytosis
Time
be-
tween Serum
TX Mean creat. con-
Time and Hct centration
on EP (HD) at the time Trans-
HD mea- last Hct at Arterial of EP plant
until sure- month time of oxygen Rel HV deternii- Hyper- artery
Patient
no. Age Sex Diagnosis
TX ment prior
months months to TX
EP deter-
mination
satu-
ration
miii .73
m2
nation
mg/di
tension steno-
Yes/No sis
Ep
mU/mi
Non-PTE
Patients
1 45 M Interstitial nephritis 13 14 25% 41% 97.8% 700 1.3 No Yes 5
2 31 F Glomerulonephritis 65 22 28% 36% 98.2% 785 1.5 No No 124
3 40 M Polycystic kidney
disease
23 9 35% 40% 97.6% 918 1.8 Yes No 9
4 31 F Glomerulonephritis 50 49 36% 38% 90.5% 705 1.0 No No 4
5 35 F Malignant
nephrosclerosis
45 57 36% 38% 97.3% 580 1.0 Yes Yes 21
6 54 M Polycystic kidney
disease
15 22 32% 40% 97.6% 784 1.4 Yes No 38
7 40 M Glomerulonephritis 48 21 24% 41% 96.8% 835 1.0 No No 17
8 51 M Glomerulonephritis 24 17 29% 37% 98.6% 822 1.3 No No 2
9 51 F Glomerulonephritis 118 23 23% 42% 97.3% 808 1.0 Yes Yes 30
10 28 M Diabetic nephrosclerosis 30 12 24% 43% 96.5% 825 1.5 Yes No 14
11 23 M Interstitial nephritis 6 12 26% 38% 96.8% — 1.8 No Yes 3
12 21 F Glomerulonephritis 12 3 24% 36% 96.5% 747 1.1 Yes Yes 5
(Range/SD) 38 6 to 3 to 29 39 96.8 783 1.3 24
118 57
PTE Patients
13 35 M Glomerulonephritis 15 30 29% 53% 97.6% 823 1.6 Yes No 831
14 33 M Glomerulonephritis 131 16 19% 49% 96.5% 1007 1.2 No Yes 58
15 51 M Interstitial nephritis 84 3 33% 49% 98.4% 790 1.7 No No 205
l6 26 M Glomerulonephritis 32 37 18% 49% 97.1% 754 1.0 No No 77
17 35 M Glomerulonephritis 12 3 18% 51% 97.6% — 1.1 Yes No 99
18 53 M Glomerulonephritis 60 4 24% 48% 97.1% 1320 1.9 Yes Yes 96
19 45 F Interstitial nephritis 45 6 26% 50% 97.1% 600 1.2 No No 44
20 46 F Interstitial nephritis 86 32 22% 50% 97.6% 824 0.8 No No 80
21 25 F Glomerulonephritis 58 25 30% 49% 95.5% 646 1.0 No Yes 75
22 48 M Glomerulonephritis 76 36 37% 50% 96.8% 775 1.6 No No 68
23 32 M Unknown 4 31 — 50% 97.1% 680 1.2 No No 124
24 43 M Unknown 42 12 18% 48% 98.0% 845 1.6 No No 159
(Range/SD) 39 4 to 3 to 25 50 97.2 824 1.3 160
131 37
Abbreviations: HD, hemodialysis; TX, transplantation; HV, heart volume.
a These patients were investigated by venous catheterization.
the hematocrit ranged from 48 to 53% (PTE patients, group A).
Blood samples for Ep determination were obtained at least 3
weeks after the last phlebotomy. Only one of four bilateral
nephrectomized patients developed polycythemia. He was not
included in this study because of congestive cardiomyopathy
and chronic persistent hepatitis.
For comparison, from non-nephrectomized patients with
normal or slightly decreased hematocrit, who never had phle-
botomy, a second group of 12 patients was selected and
designated "non-PTE patients" (group B; hematocrit, 36 to
42%). Although exact matching of the two groups was not
possible, group B was selected as close as possible to group A
with regard to underlying diagnosis, age, sex, duration of
hemodialysis before transplantation, time between transplanta-
tion and present investigation, average hematocrit while on study.
hemodialysis, arterial oxygen saturation, radiologically deter-
mined heart volume, and serum creatinine concentration, as
well as incidence of arterial hypertension and transplant artery
stenosis (Table 1). Patients with secondary polycythemia were
excluded from the study.
Four patients of the PTE group A and one patient of the non-
PTE group B underwent selective venous catheterization for Ep
determination (indicated by footnote a in Table 1). In addition,
one other patient, excluded from group B because of a low
hematocrit of 30%, was investigated by venous catheterization.
Venous blood sampling was always performed at the following
sites: (1, 2) from the two native kidneys, (3) from the grafted
kidney, (4) in the vena cava proximal to the native kidneys, and
(5) in the vena cava between the native kidneys and the graft.
All patients gave informed consent prior to inclusion in the
Assay for Ep. Serum Ep concentration was measured using
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PTE patients non-PTE Normal
patients volunteers
Fig. 1. Peripheral Ep Concentration and hematocrit of patients with
(PTE) and without (non-PTE) post-transplant erythrocytosis in compar-
ison to normal volunteers. Mean SD of Ep concentrations are
represented by the hatched columns and logarithmic scale and hemato-
crit by the dotted columns and linear scale.
the fetal mouse liver cell culture technique, as described by
Wardle et al [14] and Dunn, Jarvis, and Greenman [15] with
minor modifications: To overcome the still unsolved problems
of tracer dilution, no radioactive marker for hemoglobin synthe-
sis was used [16]. Instead, direct observation of erythroid cell
proliferation was done. As a quantitative measure for Ep the
number of colony forming units-erythroid (CFU-E) per surface
area of a semisolid culture medium was counted as described by
Rich and Kubanek [17] and Hâgâ and Falanger [18]. Fetal
mouse liver cells from fetuses 13-days-old or less were prepared
according to the technique of Iscove, Sieber, and Winterhalter
[19] as described earlier [5]. Liver cells were disaggregated and
suspended as single cells at a concentration of 80,000 cells/mi in
a culture medium, containing Eagle's minimum essential medi-
um in methylcellulose, 30% fetal calf serum (FCS, Flow Lab,
Bonn, West Germany), I ILM/ml of glutathione (oxidized), 100
U/mI of penicillin, and 100 g/ml of streptomycin. In addition,
either a commercially available Ep standard preparation (step 3,
Connaught Laboratories, Toronto, Canada) was added to the
culture at final concentrations of 32, 16, 8,4, 2, 1, and 0 mU/ml,
or a test serum at final concentrations of 20, 10, and 5%
(volume/volume). The test serum sample was previously con-
centrated by ultrafiltration in an Amicon chamber (minicon-B,
Amicon GmbH,, Witten, West Germany) equipped with a
selectively permeable membrane with a molecular cut-off of
15,000 daltons. Serum samples of 1.2 ml were diluted in sterile
saline solution and made up to a volume of 5.0 ml and
concentrated down to 0.5 ml. Thereafter, an additional concen-
tration to 0.5 ml was performed after a second dilution to 5.0 ml.
The purpose of the procedure was to concentrate the serum
sample 2.4-fold (from 1.2 to 0.5 ml), and to reduce the concen-
tration of small molecules (other than sodium chloride) of less
than 15,000 daltons to approximately 1% by predilution and
ultrafiltration. Accordingly, Ep standard was dissolved in 1.2
ml of FCS and processed through the Amicon chamber in the
same way as the serum test samples. One-half milliliter of
-70 serum concentrate or Ep standard dissolved in FCS concentrate
after serial dilution with FCS (1/1, 1/2, 1/4, and so forth) was
-60 added to 2.5 ml of Eagle's minimum essential medium contain-
ing fetal liver cells, methylcellulose, FCS, and the other ingredi-
-50 ents to render 3.0 ml, enough for triplicate measurements.
Three aliquots of 0.8 ml of cell culture prepared in this way
-40 were plated in 35 x 10-mm petri dishes and incubated for 48 hr
at 37°C in a humidified atmosphere at 95% air and 5% CO2.
After staining with diaminobenzidine [20], CFU-E of eight or
30 more cells were counted using an inverted microscope. One
sixth of the plate area was scored and considered to be
.20 representative of the total plate area.
To minimize variations in erythroid colony formation, only
.10 one stock batch of FCS and one batch of Ep (sp act 5.1 U/mg
protein) was used. For direct comparison, measurement of
• 0 corresponding sera, for example, all samples of selective cathe-
terization of one patient, was always carried out in parallel in
the same assay.
A test for significance of regression and for the absence of a
significant deviation from linearity and parallelism in the log/
dose-log/response relationship of test and standard samples was
performed using the analysis of variance [21]. Since our labora-
tory standard was calibrated against the International Standard
Preparation B (courtesy of the World Health Organization
Laboratory for Biological Standards, London, United King-
dom), Ep values are expressed in international milliunits
(mU/mi).
Minimal Ep concentration in the culture determined with
certainty was 0.5 mU/mi; the maximal test serum concentration
in the culture was 20 vol%, thus the sensitivity limit for Ep
measurements in crude serum samples was 2.5 mU/mi.
To evaluate the clinical data, we used Student's unpaired
test.
Results
Figure 1 shows the mean Ep concentration and hematocrit in
12 patients with and without PTE in comparison to 39 healthy
controls. Mean serum Ep in PTE patients of 160 216 (SD)
mU/mI is significantly higher than the mean serum Ep of 24
33 (SD) mU/ml and 25 16 (SD) mU/mi in non-PTE patients and
healthy controls, respectively (P < 0.025).
Venous catheterization in four PTE patients reveals signifi-
cantly elevated Ep concentrations in the sera derived from the
native kidneys and from the vena cava proximal to the native
kidneys of 112 49 (SD) mU/ml, 107 35 (SD) mU/ml, and 101
49 (SD) mU/mI, respectively, as compared to Ep values
measured in serum samples from the graft and from a peripheral
vein of 51 18 (SD) mU/mi and 66 15 (sD) mU/mi (P < 0.05,
Table 2). Samples derived from the vena cava between native
kidneys and graft show an intermediate Ep value of 58 14 (SD)
mU/mi.
In two non-PTE patients no difference between the Ep values
from the various sites of venous catheterization can be seen, as
shown in Table 2. They all are approximately in the same range
as those of our normal controls of 4 to 40 mU/mi.
Discussion
During the past 7 years, the fetal mouse liver cell culture
technique has become an established method for the determina-
P<0.025 I
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Table 2. Serum Ep concentration (mU/mi) in patients with (PTE) and without (non-PTE) post-transplant erythrocytosis derived from different
sites by use of selective catheterization
Patient no.a Left kidney Right kidney Graft kidney
Vena cava
above native
kidneys
Vena cava
between graft and
native kidneys Periphery
PTE patients
14 100 69 47 50 53 58
16 184 164 32 152 71 77
20 79 100 50 70 40 80
24 90 105 76 134 66 50
Mean SD 112 49 107 39 51 18 101 49 58 14 66 15
Non-PTE patients
12 25 36 15 29 23 5
25 11 19 6 16 9 3
Mean 18 28 11 21 16 4
P values
Left kidney vs. graft kidney <0.05
Right kidney vs. graft kidney < 0.05
Left kidney vs. periphery = 0.06
Right kidney vs. periphery <0.05
Graft kidney vs. periphery NS
Patient numbers are from Table 1 with the exception of no. 25 who was excluded from the non-PTE group because of a low hematocrit (see
Methods).
tion of low concentrations of Ep [22—261. After the introduc-
tion of methylcellulose as an immobilizing vehicle, the main
obstacle of the in vitro bioassay, that is, the errors resulting
from unpredictable tracer dilution of radiolabeled markers [16,
27] could be overcome by the complete omission of isotopes.
The semisolid culture technique allows the direct inspection
and quantitation of Ep-dependent erythroid cell growth, be-
cause the number of CFU-E per surface area is directly
correlated to the Ep concentration in the culture in the same
way as the hemoglobin synthesis is Ep-dependent in the liquid
cell culture [17—19]. For Ep concentrations between 0.5 to 100
mU/mi, the number of CFU-E increases steadily in a logldose-
log/response relationship. As the second modification of the
method, dialysis and concentration of serum samples were
introduced. Thus, possible uremic toxins in the low and middle
molecular range below 15,000 daltons can be removed from the
sera, and the volume of the sample is reduced allowing use of
high proportions of FCS in the culture. The increase of the FCS
concentration from 10% used in earlier experiments to 30% in
the present semisolid culture has probably improved the culture
conditions [3, 16, 28]. Our normal values obtained in 36 healthy
volunteers range from 4 to 40 mU/mi (mean, 25 mU/ml), which
is in good agreement with the majority of the accumulating data
of Ep titers obtained in the sera concentrations of normal
subjects by use of various assay techniques [27, 29, 30],
After successful kidney transplantation renal function returns
to normal. Therefore, it is not surprising that uremia-associated
disturbances such as renal anemia usually disappear several
months after transplantation. However, no convincing explana-
tion has been offered so far for the consistent observation that
in a certain percentage of transplant patients improvement of
anemia progresses more rapidly and that production of erythro-
cytes continues after complete correction of the originally
decreased red cell mass [8—10]. In general, the cause of the
resulting polycythemia can be attributed to three different
mechanisms. First, there may be autonomous red cell produc-
tion as seen in patients suffering from polycythemia rubra vera.
Secondly, red cell production may rise to increase the oxygen
transport when oxygenation is impaired as in cardiopulmonary
diseases, or when kidney oxygenation is reduced due to severe
renal artery stenosis [12], or as a consequence of kidney
infarction [3 1—33]. And thirdly, Ep production is increased
without underlying hypoxia, as can be seen in some patients
with hypernephroma, cerebellar carcinoma, or paraneoplastic
syndrome [341.
Whereas the last two possibilities are associated with in-
creased serum Ep concentrations, the first one is characterized
by decreased serum Ep levels [26, 35]. In accordance to our
clinical evaluation, we did not find a suggestion for the presence
of polycythemia vera in our PTE patients. This possibility could
clearly be ruled out by the demonstration of significantly
elevated Ep levels in these patients. The incidence of transplant
artery stenosis was not higher in the PTE patient group when
compared to non-PTE patients (3 of 12 vs. 5 of 12, Table 1). In
addition, Ep concentrations in these patients did not exceed the
respective mean Ep concentration in either group. This makes it
unlikely that transplant artery stenosis contributes significantly
to the increased Ep production in PTE patients. Pulmonary
disorders were also ruled out in every PTE patient by normal
blood gases with arterial oxygen saturations of above 95%.
These observations agree well with the results of Herforth et
al [61, who compared 12 PTE patients with a similar group of
patients with normal hematocrit. No clinical suggestion for
secondary polycythemia existed in any patient. Although these
authors did not measure Ep, they assumed that in their PTE
patients the diseased native kidneys might produce more Ep
than necessary for red cell production. This assumption was
confirmed by the studies of Dagher et al [7], who found elevated
peripheral Ep levels in six of seven patients with PTE. Ep
derived from the venous blood of the native kidneys was higher
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than that from the graft's vein, as well as that from peripheral
veins [71.
Increased Ep production from the native kidneys was an
unexpected finding since it had been long accepted that the
damaged kidneys of endstage renal failure have not only
completely lost their excretory function, but also their capabili-
ty to produce Ep. This stimulated us to investigate Ep produc-
tion in a larger number of patients and to collect blood speci-
mens from different sites of interest.
It can be shown that (1) patients with PTE had generally
higher serum Ep levels than patients with normal hematocrits
(P < 0.025), and (2) native kidney venous blood revealed
significantly higher Ep levels than both graft venous blood and
peripheral venous blood. Blood coming from the graft showed
the same Ep concentrations as that going into the graft,
indicating that Ep production within the transplanted kidney
had ceased or declined to a very low level. This observation
suggests that in contrast to the native kidneys the graft operates
within the normal feedback regulation. Why the native kidneys
escape from feedback regulation cannot be answered at pres-
ent, neither is it known whether the native kidneys produce Ep
completely unresponsive to the peripheral hemoglobin level or
whether their feedback operates at a higher level of hemoglo-
bin. Preliminary data, obtained by us pre- and post-phleboto-
my, suggest a preserved feedback regulation indicating a shifted
threshold of the oxygen sensor or a lower oxygen tension at the
sensor site due to fibrotic alteration in the diseased kidneys.
Thus, from our findings we feel the data of Dagher et al [7]
can be confirmed. Considering Ep production in endstage renal
failure more carefully, this is no longer surprising. Caro et al
[30] and our group [3, 28] can also show that Ep deficiency is
not a consistent finding in chronic renal failure and that in a
certain number of patients serum Ep concentrations are consid-
erably elevated. It is therefore reasonable to assume that
patients who develop PTE are those who have been able to
produce large amounts of Ep even before transplantation. That
increased Ep production did not result in correction of their
anemia prior to kidney transplantation was most probably due
to uremic bone marrow intoxication, thus restraining erythro-
poiesis from being adequately increased, as we have shown
recently in in vitro studies [5].
Reprint requests to Dr. H. W. Radtke, Department of Nephrology,
Center of Internal Medicine, University Hospital, Theodor-Stern-Kai 7,
D-6000 Frankfurt am Main 70, West Germany
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